Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  CANCER THERAPIES
A Global Business Report

This report analyzes the global market for Cancer Therapies in US$ Billion by the following segments: Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immunotherapy. Annual forecasts are provided for the period 2006 through 2015. A six-year historic analysis is also provided for these markets. The report profiles 208 companies including many key and niche players worldwide such as Abraxis BioScience, Inc., Amgen, Inc., AstraZeneca PLC, Bayer Schering Pharma, Biogen Idec Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cell Therapeutics, Inc., Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., Genzyme, GlaxoSmithKline, Imclone Systems, Inc., Merck KGaA, Novartis AG, Ortho Biotech Products, L.P, OSI Pharmaceuticals, Inc., Pfizer, Sanofi-Aventis, Schering Plough Corporation, Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited, and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1551  PAGES:    697
PRICE:    $3950  DATE:       February 2009
COMPANIES:  208  MARKET DATA TABLES:   316
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  CANCER THERAPIES (Complete Report) Pages : 697   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3
Chemotherapy.....I-3
Targeted Therapy.....I-3
Hormonal Therapy.....I-3
Immunotherapy.....I-3
  
II. EXECUTIVE SUMMARY108$3000
  1. Industry Overview.....II-131 $1650  
   Cancer Therapies: A Prelude .....II-1
Patent Expiries of Branded Drugs to Trigger Generic Competition.....II-1
1$100
   New Cancer Therapies Appear Over the Horizon .....II-2
New Generation Cancer Drugs and Their Area of Use.....II-2
1$100
   The New Era of Cancer Treatment.....II-3
Biotech Cancer Therapies Yet to Overcome Teething Issues.....II-3
Table 1: Global Market for Biotech-Enabled Cancer Therapies (2004 & 2008): Percentage Breakdown of Revenues by Application – Hematological, Solid Tumors, and Conditions related to Chemotherapy (includes corresponding Graph/Chart).....II-3
Targeted Therapy: The New Frontier of Cancer Treatment.....II-3
1$300
   Top Rated Targeted Cancer Therapeutics with the Potential to become Blockbuster
  Drugs Include: .....II-4
Oncology Drugs Approved for Use in the Targeted Cancer Therapeutics Sector in the
  years 2006, 2007, and 2008......II-4
1$100
   Table 2: Molecular Targeted Therapies Worldwide: Percentage Breakdown of Molecular Targeted Therapies Under Pipeline by Drug Class as of 2006 (includes corresponding Graph/Chart).....II-5
Combination Therapy: A Double Whammy Success.....II-5
Small Cap Companies: A Target of Private Capital Financing .....II-5
1$300
   Drugs (that are both available and under pipeline) Developed by the Four Small-Cap
  Companies.....II-6
1$100
   Table 3: Venture Capital Investment (In US$ Millions) Made in Research and Development of Biotechnology for the years 2004 and 2009 (includes corresponding Graph/Chart).....II-7
Shifting Therapeutic Preferences.....II-7
1$300
   Table 4: Global Market for Antihormonal Therapy (2005 and 2014): Percentage Breakdown of Revenues by Drug Class – LHRH Analogs, Aromatase Inhibitors, Anti-androgens, Anti-estrogens, and Other Hormone Antagonists(includes corresponding Graph/Chart).....II-8
Innovations in Cancer Drug Delivery: A Key Factor in Product Differentiation .....II-8
Personalized Medicine: Gain in Importance.....II-8
1$300
   Growth Drivers In a Capsule.....II-9
Rise in Cancer Incidences & Access to Modern Therapeutics Foster Growth.....II-9
Demographics & Lifestyles Raise the Risk of Cancer.....II-9
1$100
   Cancer Prone Sites based on Age.....II-10
Table 5: Population of People Aged More than 65 Years in United States for the years 2000, 2010, and 2020 (includes corresponding Graph/Chart).....II-10
Unmet Needs Leave Scope for Further Research and Development .....II-10
Low Entry Barriers in Cancer Research Encourages Breakthrough Developments.....II-10
1$300
   Increasing Investments by National Health Authorities.....II-11
Efficiency & High Prices Magnetize Manufacturers.....II-11
Supportive Cancer Drugs Contribute to Growth .....II-11
Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth.....II-11
1$100
   Table 6: Global Cancer Diagnostics Market (2004): Breakdown of Sales by Geographic Region (In US$ Billion) (includes corresponding Graph/Chart).....II-12
Molecular Imaging of Cancer: Critical in Improving Patient Outcomes.....II-12
1$300
   Innovations, Improvements, and Approvals Propel Growth.....II-13
Growth Restraints .....II-13
High Prices of Targeted Therapies Act as a Speed Breaker.....II-13
1$100
   Table 7: Average Costs of Cancer Therapies in the US as of the Year 2005 in US$.....II-14
Limited Tumor Specificity and Toxicity.....II-14
Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
  .....II-14
Reduced Smoking.....II-14
1$300
   Reimbursement and Coverage Remains a Major Challenge.....II-15
Changes in Reimbursement Policies Influence Market Prospects .....II-15
Multiple Drug Resistance.....II-15
1$100
   Stringent Regulations Delay Market Approval.....II-16
Challenges Encountered in Clinical Trials.....II-16
High Development Costs Retracts Manufacturers in Developing Countries .....II-16
Notes From Across the Globe.....II-16
United States.....II-16
Medicare Restructures its Coverage for Chemotherapy.....II-16
1$100
   Personalized Care for Cancer Treatment in US.....II-17
Drugs in Development in the US.....II-17
Chemotherapy Drugs Undergoing Trials for Breast Cancer Treatment in United States
  (as of 2007).....II-17
1$100
   Hormonal Therapy Drugs Undergoing Trials for Breast Cancer Treatment in United
  States (as of 2007).....II-18
Targeted Therapy Drugs Undergoing Trials for Breast Cancer Treatment in United
  States (as of 2007).....II-18
1$100
   Statistical Findings .....II-19
Table 8: US Market for Hospital Cancer Therapies (2004 and 2009): Percentage Breakdown of Revenues by Treatment Type – Surgery, Chemotherapy Drugs, Radiation Therapy, Biotechnology-Based Drugs, and Others (includes corresponding Graph/Chart).....II-19

Table 9: US Demand for Chemotherapy Drugs (2004 and 2009): Percentage Breakdown of Revenues by Drug Class - Alkylating Agents & Related, Antimetabolites & Related, Mitotic Inhibitors, and Others (includes corresponding Graph/Chart).....II-19
1$300
   Table 10: US Market for Multiple Myeloma (2006): Percentage Revenue Breakdown of Leading Players – Celgene Corporation, Millennium Pharmaceuticals, Inc., Ortho Biotech, and Others (includes corresponding Graph/Chart).....II-20

Table 11: New Cancer Cases and Deaths in United States in the year 2006 (includes corresponding Graph/Chart).....II-20
1$300
   Table 12: US Market for Cancer Therapies (2004): Percentage Revenue Breakdown of Leading Players – Genentech, Sanofi-Aventis, AstraZeneca, Bristol-Myers Squibb, Pfizer, Eli Lilly, Novartis, Roche and Others (includes corresponding Graph/Chart).....II-21

Table 13: US Market for Breast Cancer Therapeutics (2006): Percentage Breakdown of Revenues by Segment: Cytotoxic Therapeutics, Hormonal Therapeutics, and Targeted Therapeutics (includes corresponding Graph/Chart).....II-21
1$300
   Canada.....II-22
Table 14: New Cases of Cancer Incidences and Deaths in Canada in the year 2006 (includes corresponding Graph/Chart).....II-22
1$300
   Australia.....II-23
Asia.....II-23
India.....II-23
1$100
   Japan.....II-24
Korea.....II-24
Malaysia.....II-24
Table 15: Imports of Cancer Diagnostic and Therapy Equipment (2004): Percentage Breakdown of Import Value by Country of Origin (includes corresponding Graph/Chart).....II-24
Europe.....II-24
1$300
   Advancements in Breast Cancer Treatment in Europe.....II-25
New Formulations that are Under Clinical Trials.....II-25
1$100
   Table 16: European Market for Breast Cancer Therapeutics (2006): Percentage Breakdown of Revenues by Drug Class: Cytotoxic Drugs, Hormonal Drugs, and Biologics (includes corresponding Graph/Chart).....II-26
Drugs Undergoing Trials for Bladder Cancer Treatment in Europe As of 2006.....II-26
1$300
   Latin America.....II-27
Brazil.....II-27
Mexico.....II-27
Argentina.....II-27
1$100
   Cancer Incidences Worldwide .....II-28
Table 17: New Incidences of Liver Cancer (in ‘000) Worldwide for the years 2008 and 2012.....II-28
1$300
   Table 18: New Incidences of Breast Cancer (in ‘000) Worldwide for the years 2008 and 2012.....II-291$300
   Table 19: New Incidences of Prostate Cancer (in ‘000) Worldwide for the years 2008 and 2012.....II-301$300
   Table 20: New Incidences of Bladder Cancer (in ‘000) Worldwide for the years 2008 and 2012.....II-31
1$300
  2. Product Overview.....II-3217 $1350  
   Cancer: A Major Health Crises in the Modern World.....II-32
Table 21: Cancer Causes in Developed and Developing Countries (2006): Percentage Breakdown by Risk Factors – Diet or Nutrition, Infections, Tobacco, and Other Factors (includes corresponding Graph/Chart).....II-32
Types of Cancers.....II-32
1$300
   Prostate Cancer.....II-33
Key Prostate Cancer Drugs & Companies.....II-33
Breast Cancer.....II-33
1$100
   Key Breast Cancer Drugs & Companies.....II-34
Cervical Cancer.....II-34
Colorectal Cancer.....II-34
1$100
   Key Colorectal Cancer Drugs & Companies.....II-35
Lung Cancer.....II-35
1$100
   Key Lung Cancer Dugs & Companies.....II-36
Renal Cancer .....II-36
Key Renal Cancer Drugs and Companies.....II-36
Skin Cancer.....II-36
1$100
   Non-Hodgkin’s Lymphoma.....II-37
Leukemia.....II-37
Pancreatic Cancer.....II-37
Bladder Cancer.....II-37
Endometrial Cancer.....II-37
Cancer Therapies: A Review.....II-37
1$100
   Monoclonal Antibodies Open Up A New Era in Cancer Treatment.....II-38
List of Approved Monoclonal Antibodies Used in Treating Various Cancers.....II-38
1$100
   Therapeutic Cancer Vaccines: Harnessing the Immune System to Fight Cancer.....II-39
Cancer Vaccine Strategies.....II-39
1$100
   Therapeutic Cancer Vaccine Products Under Clinical Trials as of 2007.....II-40
Gene Therapy.....II-40
Types of Cancer Therapies.....II-40
Chemotherapy.....II-40
1$100
   Chemotherapy Drugs Require Careful Handling.....II-41
Types of Chemotherapy.....II-41
1$100
   Chemotherapy Drug Classes.....II-42
Risks Associated with Chemotherapy.....II-42
1$100
   When Chemotherapy Fails .....II-43
Targeted Therapy.....II-43
1$100
   Table 22: Targeted Therapies Market Worldwide (2006): Percentage Breakdown of Targeted Therapeutic Drugs Under Various Stages of Development (includes corresponding Graph/Chart).....II-44
Hormonal Therapy.....II-44
Hormonal Therapy Strategies.....II-44
1$300
   Drug Classes in Hormone Therapy.....II-45
Drugs Used in Hormone Therapy and Their Uses.....II-45
1$100
   Side-Effects Associated with the Use of Various Drugs in Hormone Therapy.....II-46
Immunotherapy.....II-46
A Primer.....II-46
1$100
   Immunotherapy Treatment Strategies .....II-471$100
   Second-Generation Immunotherapies.....II-48
Table 23: Global Market for Immunotherapy (2007 and 2012): Percentage Breakdown of Revenues by Drug Class –Monoclonal Antibodies, Biological Response Modifiers, Vaccines, and Other Immunotherapy Products (includes corresponding Graph/Chart).....II-48
1$300
  3. Drug Approvals and Clinical Trials.....II-4919 $1000  
   ABRAXANE Gains Marketing Approval in Korea, Australia and Other Countries.....II-49
GlaxoSmithKline's Cervarix Finds Place in UK National Immunization Programme .....II-49
1$100
   Biogen Idec and Elan Commence Clinical Trial of TYSABRI.....II-50
Calistoga Pharmaceuticals Starts Phase I Clinical Trial of CAL-101.....II-50
Progen Pharmaceuticals Continues Phase 1 Development of PG-11047.....II-50
GlaxoSmithKline Receives Conditional EU Approval for Marketing Lapatinib .....II-50
Roche’s Xeloda Gains EU Approval for Use in Colorectal Cancer Treatment.....II-50
1$100
   Genentech Secures FDA Approval for Avastin.....II-51
EU Approves Four Biosimilar Versions of Neupogen.....II-51
Russia Approves Oncophage for Kidney Cancer Treatment.....II-51
Eisai to Start Clinical Testing of MORAb-028.....II-51
Threshold Pharmaceuticals Starts Phase I/II Clinical Trials of TH-302.....II-51
AVEO Commences Phase 1b Clinical Study of AV-951 and FOLFOX6 .....II-51
1$100
   GSK’s Tykerb Receives USFDA Approval.....II-52
Seattle Genetics Initiates Phase 1b Clinical Trials of SGN-40 with Gemzar and
  Rituxan.....II-52
S*Bio Initiates Phase I Clinical Trials of SB1518.....II-52
Merck Serono Initiates Phase III Trials of Cladribine.....II-52
BioCurex Receives Patent for RECAF Technology Applications.....II-52
Chidamide/HBI-8000 Completes Phase I Clinical Trials in China.....II-52
1$100
   AVEO Initiates Phase I Trials of AV 299.....II-53
Exelixis Completes Phase I Trials of XL765 .....II-53
Infinity Pharmaceuticals Starts Phase I Clinical Trial of IPI-926.....II-53
Cell Genesys Terminates its VITAL-1 Phase 3 Trial of GVAX.....II-53
GTx Completes Phase II Clinical Trials of Ostarine.....II-53
1$100
   Imclone Awaits Approval for Erbitux from US Medicine Regulator.....II-54
Kuhnil and Daiichi Sankyo Initiate Phase II Clinical Trial of Nimotuzumab.....II-54
Peplin Starts Phase III Clinical Trials of PEP005 Gel.....II-54
ERBITUX Receives Marketing Approval in Japan.....II-54
Progenics Starts Phase I Clinical Study of PSMA ADC.....II-54
FDA Awards Orphan Drug Designation for the Use of Stem Cell Technology in Bone Marrow
  Transplantations.....II-54
1$100
   Roche, OSI and Chugai Receive Approval for Tarceva in Japan.....II-55
Eisai Receives FDA Approval for ONTAK®.....II-55
Genmab Terminates the Development of HuMax-CD4 .....II-55
Teva Pharmaceutical Acquires EU Authorization to Market Neutropenia Drug.....II-55
Novartis’ Everolimus Awaits Approvals from US FDA, Swissmedic, and EMEA.....II-55
1$100
   Abraxis BioScience, AstraZeneca, and NCCN to Conduct Anti-cancer Drug Studies.....II-56
Sanofi-Aventis Receives Japanese Approval for Taxotere® Injection .....II-56
Roche’s Avastin Bags European Approval for Renal Cancer Treatment.....II-56
Roche Announces European Approval of Herceptin.....II-56
1$100
   GSK’s Hycamtin Obtains FDA Approval.....II-57
Avastin Receives European Approval for Breast Cancer Treatment.....II-57
Roche’s Tarceva Obtains European Approval.....II-57
Roche’s NeoRecormon Gains European Approval.....II-57
Northwest Biotherapeutics’ DCVax-Brain Gains Swiss Approval.....II-57
1$100
   Alfacell’s ONCONASE Receives Orphan Drug Designation from US.....II-58
Cougar Biotechnology Commences Phase II Trial of CB7630.....II-58
Lorus Therapeutics Receives Orphan Drug Designation for its LOR-2040.....II-58
Merck Serono Receives EU Approval for mCRC Treatment With Erbitux .....II-58
MGI PHARMA and HELSINN Receive FDA Approval for Aloxi .....II-58
FDA Grants Approval for Sutent, a Kidney and Gastrointestinal Cancer Drug.....II-58
1$100
   Wyeth Pharmaceuticals’ TORISEL Receives FDA Approval.....II-59
Dabur Pharma Acquires FDA Approval for Paclitaxel Injection.....II-59
EUSA’s CAPHOSOL Finds Application in Treating Oral Mucositis.....II-59
European Commission Approves Amgen’s Vectibix for Metastatic Colorectal
  Cancer.....II-59
GPC Biotech Starts Phase 2 Trials of Satraplatin plus with Tarceva.....II-59
1$100
   FDA Approves Vectibix as Treatment for Metastatic Colorectal Cancer .....II-60
FDA Approves IND Indication for CYT-500 of Cytogen .....II-60
FDA Clears Rituxan for New Indications.....II-60
Epeius Receives BFAD Approval for Expanded Access Program for Rexin- G.....II-60
1$100
   BioMedicines Initiates Phase 1b Study of Biomed 101.....II-61
Avastin Obtains FDA Approval for Treating Recurrent Colorectal Cancer.....II-61
Genentech’s Herceptin Gains FDA Nod for Treating Early stage Cancer after Surgery
  .....II-61
1$100
   Epeius Starts Phase I and II Trials of the New Tri-Rex Vaccination Protocol .....II-62
Sonus Begins Phase 1 Clinical Trial of TOCOSOL® Camptothecin.....II-62
Dynavax Begins Phase 1 Clinical Trial of TLR9 agonist Combined with Chemotherapy
  Regimen .....II-62
Morphotek’s MORAb-009 Receives Orphan Drug Designation .....II-62
1$100
   Morphotek’s MORAb-003 Receives Orphan Drug Status from the US FDA .....II-63
Morphotek Grants FDA Approval of the IND for MORAb-009.....II-63
MannKind Receives IND Clearance for MKC1106-PP Immunotherapy .....II-63
1$100
   Pharmexa Initiates Phase II trials of GV 1001.....II-64
Wyeth Pharmaceuticals Declares Discontinuation of Phase III Clinical Trials for
  Temsirolimus.....II-64
OXiGENE Announces Clinical Trials of CA4P.....II-64
Glaxo SmithKline’s Hycamtin Gains FDA Approval for Treating Cervical Cancer.....II-64
1$100
   Cell Genesys Announces the Initiation of Amplified Phase I Trial of CG0070.....II-65
Genentech’s Avastin Receives FDA Approval for Lung Cancer Treatment .....II-65
Vorinostat Acquires FDA Approval for Skin Cancer Treatment.....II-65
Callisto Launches the First Clinical Trial of Landmark Discovery, L-Annamycin for
  ALL.....II-65
1$100
   Shanghai Sunway Biotech’s H101 Receives Marketing Approval in China.....II-66
Northwest Biotherapeutics Gains Patent for CXCR4.....II-66
1$100
   Biocon’s Cancer Drug Initiates Phase II Trials .....II-67
1$100
  4. New Drug Developments and Launches.....II-682 $200  
   GSK Launches Cervarix in Singapore.....II-68
Abeome Launches New Stem Cell Monoclonal Antibody.....II-68
Dabur Pharma Launches a New Drug Delivery System, Nanoxel.....II-68
Epeius Biotechnologies Develops New Targeted Anti-Cancer Drugs.....II-68
1$100
   Monash University Scientists Develop siRNA for Cancer Treatment.....II-69
Cytogen Introduces SOLTAMOX™, the First Hormonal Breast Cancer Therapy .....II-69
1$100
  5. Recent Industry Activity.....II-7023 $1200  
   Avexa to Acquire Progen Pharmaceuticals.....II-70
Abraxis Takes Over Platco and Shimoda.....II-70
WEHI Collaborates with Abbott and Genentech.....II-70
Novartis Inks a Production Deal with Lonza.....II-70
1$100
   Roche to Take Over UK-Based Biotech Company, Piramed.....II-71
Pfizer Acquires Encysive.....II-71
Eden Biodesign Inks a Marketing Services Deal with Human Genome Sciences.....II-71
FivePrime Join Hands with Pfizer for Cancer and Diabetes Research.....II-71
1$100
   Sanofi-Aventis and Dyax Ink Two Antibody Pacts.....II-72
Pfizer and AVANT Ink a Global Licensing Agreement for CDX-110.....II-72
1$100
   Takeda Inks an Exclusive Partnership Agreement with Amgen.....II-73
Genentech and Roche Ink a Licensing Agreement with Glycart.....II-73
Bristol-Myers Squibb to Acquire Kosan Biosciences.....II-73
Nabi Biopharmaceuticals Collaborates with NIAID.....II-73
1$100
   Pfizer to Acquire Serenex.....II-74
Morphotek Signs an Agreement with Pivotal BioSciences.....II-74
GE Healthcare Inks a Three-Year Agreement with Eli Lilly.....II-74
ArQule Signs Two Agreements with Daiichi Sankyo.....II-74
1$100
   Circadian Completely Acquires Vegenics Limited.....II-75
Lpath Inks an Accord with Merck Serono.....II-75
Topex Expands its Distribution Deal with Therapy Remarketing.....II-75
Unibioscreen Inks a Partnership Agreement with Drais Pharmaceuticals.....II-75
Avant Immunotherapeutics to Become Celldex Therapeutics .....II-75
1$100
   Abraxis Enters into Definitive License Agreements with ProMetic Life Sciences.....II-76
Biovest International to Receive US$1.6 Million Funding for Biomedical
  Research.....II-76
Access Completes the Acquisition of Somanta.....II-76
Clinical Data Inks an Agreement to Take Over Avalon Pharmaceuticals.....II-76
1$100
   EUSA Pharma Acquires Cytogen Corporation.....II-77
Oncologic Merges with Triton BioSystems .....II-77
Eli Lilly to Take Over ImClone Systems.....II-77
CEL-SCI Establishes a New Manufacturing Unit.....II-77
1$100
   ZaBeCor Establishes Biothorpe Pharmaceuticals, a New Subsidiary.....II-78
Takara Bio Signs a Research Agreement with a Chinese University.....II-78
Shanghai Roche Expands its MabThera Marketing Activities .....II-78
Merck Completes the Acquisition of Majority Stake in Serono.....II-78
Merck Enters into Licensing and Collaboration Agreement With Idera.....II-78
1$100
   Sanofi-Aventis Inks a Global Licensing Deal with Oxford BioMedica.....II-79
WEHI to Collaborate with Genentech and Roche.....II-79
AstraZeneca Acquires MedImmune.....II-79
Antisoma Enters into a Global Accord with Novartis.....II-79
Sanofi-Aventis and Astellas Pharma to Restructure their JV Operations in Japan
  .....II-79
1$100
   Biomira Amends its Agreements with Merck.....II-80
AstraZeneca Takes Over Canadian Biologics Plant.....II-80
Pfizer to Acquire Coley Pharmaceutical Group.....II-80
Abraxis Takes Over Watson’s Manufacturing Facility.....II-80
1$100
   Abraxis Takes Over Pfizer’s Cruce Davila Manufacturing Facility.....II-81
Bristol-Myers Squibb to Take Over Adnexus Therapeutics.....II-81
Merck to Partner with a Florida-based Research Center.....II-81
Organon to Partner with Medarex.....II-81
1$100
   Genzyme to Acquire Bioenvision.....II-82
Genentech Inks a Deal with Seattle Genetics.....II-82
TopoTarget Takes Over Apoxis.....II-82
Roche to Acquire CuraGen’s Subsidiary .....II-82
GPC Biotech Inks an Agreement with Yakult.....II-82
MediGene Acquires Avidex.....II-82
1$100
   Sanofi-Aventis Inks an Agreement with Taiho.....II-83
Biogen Inks Merger Agreement with Conforma.....II-83
Roche Signs a Merger Agreement with Ventana.....II-83
1$100
   Roche Takes Over THP to Enhance Its Therapeutic Antibody Profile.....II-84
ImClone Systems and Merck Revise ERBITUX Agreement.....II-84
GSK Invests €500 Million in France.....II-84
Amgen Takes Over Avidia.....II-84
Moores Cancer Center Collaborates with Medarex.....II-84
1$100
   ADITUS Medical Forms an Alliance with IGEA.....II-85
Callisto Opens Site For Phase–II Clinical Trials of Atiprimod.....II-85
XOMA Inks an Agreement with Attenuon.....II-85
AstraZeneca Joins Schering to Develop a Novel Breast Cancer Drug.....II-85
1$100
   Nventa To Procure Hiltonol from Oncovir Incorporated.....II-86
MaxCyte and Medinet Sign an Agreement for Immuno-Cell Therapy.....II-86
Receptor Acquires Cancer Vaccine ‘G17DT’ from Aphton.....II-86
1$100
   Enzon Collaborates with Santaris for Joint Development ff Novel RNA
  Antagonists.....II-87
Epeius Receives Funding from Lazarex for Rexin-G™ Trials .....II-87
Callisto Inks a Deal with M.D. Anderson Cancer Center.....II-87
1$100
   AstraZeneca Inks an Agreement with Abraxis BioScience.....II-88
diaDexus and BVF Establish CFD Therapeutics .....II-88
Merck to Acquire US Rights for Liposome Vaccine.....II-88
1$100
   Genentech Enters Into Alliance with Inotek.....II-89
AstraZeneca to Take Over KuDOS Pharmaceuticals.....II-89
Genentech Collaborates with Accelerate Brain Cancer Cure.....II-89
1$100
   Sonus and Schering Enter into a Global Licensing Agreement.....II-90
Abgenix Inks Merger Agreement with Amgen.....II-90
1$100
   AstraZeneca and Astex Enter into an Alliance.....II-91
Pfizer Inks Global License Pact with Coley Pharmaceutical Group.....II-91
Genzyme Takes Over ILEX Oncology.....II-91
1$100
   Genentech and CGI Enter into an Exclusive Agreement.....II-92
Genzyme to Acquire AnorMED.....II-92
1$100
  6. Focus on Select Players.....II-9314 $800  
   Abraxis BioScience, Inc. (USA).....II-93
Amgen, Inc. (USA).....II-93
AstraZeneca PLC (UK).....II-93
2$200
   Bayer Schering Pharma (Germany).....II-95
Biogen Idec Inc (USA).....II-95
1$100
   Bristol-Myers Squibb Company (USA).....II-96
Celgene Corporation (USA).....II-96
Cell Therapeutics, Inc. (USA).....II-96
1$100
   Cephalon, Inc. (USA).....II-97
Chugai Pharmaceutical Co., Ltd. (Japan).....II-97
1$100
   Eli Lilly and Company (USA).....II-98
F. Hoffmann-La Roche Ltd (Switzerland).....II-98
1$100
   Genentech, Inc. (USA).....II-99
Genzyme (USA).....II-99
GlaxoSmithKline (UK).....II-99
2$200
   Imclone Systems, Inc (USA).....II-101
Merck KGaA (Germany).....II-101
1$100
   Novartis AG (Switzerland).....II-1021$100
   Ortho Biotech Products, L.P (USA).....II-103
OSI Pharmaceuticals, Inc. (USA).....II-103
Pfizer (USA).....II-103
1$100
   Sanofi-Aventis (France).....II-1041$100
   Schering Plough Corporation (USA).....II-105
Seattle Genetics, Inc. (USA).....II-105
Takeda Pharmaceutical Company Limited (Japan).....II-105
1$100
   Wyeth (USA).....II-106
1$100
  7. Market Perspective.....II-107   
   Table 24: Global Recent Past, Current & Future Analysis for Cancer Therapies by Type – Targeted Therapy, Chemotherapy, Hormone Therapy, and Immunotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-107

Table 25: Global Historic Review for Cancer Therapies by Type – Targeted Therapy, Chemotherapy, Hormone Therapy, and Immunotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Billion for Years 2000 through 2005 (includes corresponding Graph/Chart).....II-107
1$300
   Table 26: Global 10-Year Perspective for Cancer Therapies by Type - Percentage Breakdown of Dollar Sales for Targeted Therapy, Chemotherapy, Hormone Therapy, and Immunotherapy for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1081$300
III. COMPETITIVE LANDSCAPE 570$995
  
Total Companies Profiled: 207 (including Divisions/Subsidiaries - 226)

Region/Country                 Players


The United States                137
Canada                            12
Japan                              8
Europe                            48 
     France                        7
     Germany                       5
     The United Kingdom            8
     Italy                         1
     Spain                         3
     Rest of Europe               24
Asia-Pacific (Excluding Japan)    14
Latin America                      1
Middle East                        6
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.